{"id":4562,"date":"2025-07-08T06:06:02","date_gmt":"2025-07-08T13:06:02","guid":{"rendered":"https:\/\/www.fziomed.com\/usa\/?p=4562"},"modified":"2025-07-08T06:06:04","modified_gmt":"2025-07-08T13:06:04","slug":"fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery","status":"publish","type":"post","link":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/","title":{"rendered":"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>Oxiplex is the only FDA authorized intraoperative gel indicated as an adjunct to lumbar spinal surgery to reduce postoperative leg pain and neurological symptoms.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Oxiplex gel has the potential to become a new standard of care as an adjunctive therapy.<\/em><\/p>\n\n\n<p style=\"font-weight: 400\"><strong>SAN LUIS OBISPO, California, July 8, 2025 \u2014 Fziomed, Inc.<\/strong> (\u201cFziomed\u201d or the \u201cCompany\u201d), a recognized global leader in postsurgical adhesion prevention, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo classification and marketing authorization for Oxiplex<sup>\u00ae<\/sup> gel, indicated for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. Oxiplex is now the first and only FDA authorized intraoperative gel specifically designed for this indication.<\/p>\n<p style=\"font-weight: 400\">\u201cThe FDA De Novo process is a rigorous regulatory pathway utilized when there is no substantially equivalent predicate device to reference,\u201d said Paul Mraz, President and CEO. \u201cTo satisfy FDA\u2019s benefit-risk criteria, Fziomed submitted Level 1 clinical evidence from multiple U.S. randomized clinical trials, along with international post-marketing studies, demonstrating Oxiplex\u2019s strong safety profile and clinical benefit. With this robust clinical evidence and over 20 years of real-world use outside the United States, we are confident Oxiplex has the potential to become a new standard of care as an adjunctive therapy.\u201d<\/p>\n<p style=\"font-weight: 400\">\u201cOxiplex represents an important new adjunctive treatment for spine surgeons in the United States to address a significant unmet clinical need,\u201d said Jeffrey Fischgrund, MD, Chairman of the Orthopedic Department at William Beaumont University Hospital (Royal Oak, MI) and principal investigator of the Oxiplex clinical studies. \u201cThanks to the commitment of our clinical sites, study coordinators, and patients, this technology is now available to benefit U.S. patients.\u201d<\/p>\n<p style=\"font-weight: 400\">Fziomed\u2019s Oxiplex is a safe, easy-to-use, absorbable, clear viscoelastic gel applied to tissues and surrounding anatomy during surgery, immediately prior to closure. In spine surgery, Oxiplex acts as a temporary physical barrier between adjacent tissues and has been shown in multiple peer-reviewed publications to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has been available outside the United States since 2002 and has been used in more than 750,000 spine procedures worldwide for postoperative adhesion prevention.<\/p>\n<p style=\"font-weight: 400\">\u201cThis De Novo grant from FDA represents a major milestone for Fziomed,\u201d said Gere diZerega, MD, Medical Director. \u201cIt is the culmination of extensive clinical and regulatory work, and the first step in making our platform of intraoperative gel technologies available to U.S. patients across a range of surgical disciplines \u2013 such as spine, tendon, nerve, women\u2019s health, and general surgery.\u201d<\/p>\n<p style=\"font-weight: 400\">\u201cWe are excited to achieve this important milestone and bring Oxiplex to the U.S. market,\u201d added Ron Haynes, Executive Chairman and co-Founder. \u201cThis achievement highlights the strength of our science and the dedication of our world-class team.\u201d<\/p>\n<p style=\"font-weight: 400\"><strong>About Fziomed, Inc.<\/strong><\/p>\n<p style=\"font-weight: 400\">Pioneering biomaterials since 1996, Fziomed is a vertically integrated medical device company focused exclusively on preserving surgical excellence in spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures. Fziomed develops, manufactures, and commercializes surgical biomaterials used by clinicians to improve surgical outcomes and is a global leader in postsurgical adhesion prevention.<\/p>\n<p style=\"font-weight: 400\">Fziomed\u2019s synthetic, clear, absorbable gel formulations are based on the Company\u2019s proprietary dual-polymer technology platform that provide a temporary, physical separation of tissues during the body\u2019s natural healing process \u2013 reducing adhesion formation. Fziomed\u2019s portfolio of adhesion barrier products are marketed in more than 70 countries under various brand names and have been used clinically since 2002 in nearly 1 million procedures worldwide.<\/p>\n<p style=\"font-weight: 400\">Fziomed is headquartered in San Luis Obispo, California, and has been named one of the <em>Best Places to Work in Southern California<\/em> for the past 3 consecutive years.<\/p>\n<p style=\"font-weight: 400\">Visit <a href=\"http:\/\/www.fziomed.com\/usa\/\">fziomed.com<\/a> to learn more about Fziomed and our industry-leading products.<\/p>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oxiplex is the only FDA authorized intraoperative gel indicated as an adjunct to lumbar spinal surgery to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has the potential to become a new standard of care as an adjunctive therapy. SAN LUIS OBISPO, California, July 8, 2025 \u2014 Fziomed, Inc. (\u201cFziomed\u201d or the \u201cCompany\u201d), a [&hellip;]<\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[44],"tags":[],"class_list":["post-4562","post","type-post","status-publish","format-standard","hentry","category-news-releases","pmpro-has-access"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery - Fziomed USA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery - Fziomed USA\" \/>\n<meta property=\"og:description\" content=\"Oxiplex is the only FDA authorized intraoperative gel indicated as an adjunct to lumbar spinal surgery to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has the potential to become a new standard of care as an adjunctive therapy. SAN LUIS OBISPO, California, July 8, 2025 \u2014 Fziomed, Inc. (\u201cFziomed\u201d or the \u201cCompany\u201d), a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/\" \/>\n<meta property=\"og:site_name\" content=\"Fziomed USA\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-08T13:06:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-08T13:06:04+00:00\" \/>\n<meta name=\"author\" content=\"Ryan Bledsoe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ryan Bledsoe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/\"},\"author\":{\"name\":\"Ryan Bledsoe\",\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/#\\\/schema\\\/person\\\/2154d83646a79bef9885ce67ea06a0a4\"},\"headline\":\"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery\",\"datePublished\":\"2025-07-08T13:06:02+00:00\",\"dateModified\":\"2025-07-08T13:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/\"},\"wordCount\":619,\"commentCount\":0,\"articleSection\":[\"News Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/\",\"url\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/\",\"name\":\"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery - Fziomed USA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/#website\"},\"datePublished\":\"2025-07-08T13:06:02+00:00\",\"dateModified\":\"2025-07-08T13:06:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/#\\\/schema\\\/person\\\/2154d83646a79bef9885ce67ea06a0a4\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/#website\",\"url\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/\",\"name\":\"Fziomed USA\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/#\\\/schema\\\/person\\\/2154d83646a79bef9885ce67ea06a0a4\",\"name\":\"Ryan Bledsoe\",\"url\":\"https:\\\/\\\/www.fziomed.com\\\/usa\\\/author\\\/rbledsoe\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery - Fziomed USA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/","og_locale":"en_US","og_type":"article","og_title":"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery - Fziomed USA","og_description":"Oxiplex is the only FDA authorized intraoperative gel indicated as an adjunct to lumbar spinal surgery to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has the potential to become a new standard of care as an adjunctive therapy. SAN LUIS OBISPO, California, July 8, 2025 \u2014 Fziomed, Inc. (\u201cFziomed\u201d or the \u201cCompany\u201d), a [&hellip;]","og_url":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/","og_site_name":"Fziomed USA","article_published_time":"2025-07-08T13:06:02+00:00","article_modified_time":"2025-07-08T13:06:04+00:00","author":"Ryan Bledsoe","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ryan Bledsoe","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/#article","isPartOf":{"@id":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/"},"author":{"name":"Ryan Bledsoe","@id":"https:\/\/www.fziomed.com\/usa\/#\/schema\/person\/2154d83646a79bef9885ce67ea06a0a4"},"headline":"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery","datePublished":"2025-07-08T13:06:02+00:00","dateModified":"2025-07-08T13:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/"},"wordCount":619,"commentCount":0,"articleSection":["News Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/","url":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/","name":"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery - Fziomed USA","isPartOf":{"@id":"https:\/\/www.fziomed.com\/usa\/#website"},"datePublished":"2025-07-08T13:06:02+00:00","dateModified":"2025-07-08T13:06:04+00:00","author":{"@id":"https:\/\/www.fziomed.com\/usa\/#\/schema\/person\/2154d83646a79bef9885ce67ea06a0a4"},"breadcrumb":{"@id":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.fziomed.com\/usa\/fziomed-gains-fda-de-novo-classification-grant-and-marketing-authorization-for-oxiplex-gel-in-spine-surgery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fziomed.com\/usa\/home\/"},{"@type":"ListItem","position":2,"name":"Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex\u00ae\u00a0Gel in Spine Surgery"}]},{"@type":"WebSite","@id":"https:\/\/www.fziomed.com\/usa\/#website","url":"https:\/\/www.fziomed.com\/usa\/","name":"Fziomed USA","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fziomed.com\/usa\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fziomed.com\/usa\/#\/schema\/person\/2154d83646a79bef9885ce67ea06a0a4","name":"Ryan Bledsoe","url":"https:\/\/www.fziomed.com\/usa\/author\/rbledsoe\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/posts\/4562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/comments?post=4562"}],"version-history":[{"count":0,"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/posts\/4562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/media?parent=4562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/categories?post=4562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fziomed.com\/usa\/wp-json\/wp\/v2\/tags?post=4562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}